Current frontline endocrine treatment options for women with hormone receptorpositive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer
Despite the recent advances in breast cancer early detection and awareness, a significant portion of patients present with an advanced-stage disease and more patients will progress to stage IV despite adequate treatment of their initial early-stage disease. Hormone receptor (HR)-positive, Human Epid...
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Ráidu: | Hematology/Oncology and Stem Cell Therapy |
| Fáttát: | |
| Liŋkkat: | https://journals.lww.com/10.1016/j.hemonc.2018.04.002 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
